Karyopharm Therapeutics (25K0) Ownership - Who Owns Karyopharm Therapeutics?
Karyopharm Therapeutics (25K0) Ownership Overview
- 3.63% Insiders
- 19.83% Mutual Funds
- 0.16% Other Institutional Investors
- 9.56% ETFs
- 66.82% Public Companies and Individual Investors
The ownership structure of Karyopharm Therapeutics (DE:25K0) stock is a mix of institutional, retail, and individual investors. Approximately 29.55% of the company’s stock is owned by Institutional Investors, 3.63% is owned by Insiders, and 66.82% is owned by Public Companies and Individual Investors.
The ownership structure of Karyopharm Therapeutics (DE:25K0) stock is a mix of institutional, retail, and individual investors. Approximately 29.55% of the company’s stock is owned by Institutional Investors, 3.63% is owned by Insiders, and 66.82% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Peter Kolchinsky | 1,917,354 | Institution | 8.45% | 1,422,677 |
| BlackRock, Inc. | 1,418,799 | Institution | 6.26% | 1,052,749 |
| Mutual Fund Series Trust | 1,125,000 | Institution | 4.96% | 834,750 |
| Vanguard | 1,076,752 | Institution | 4.75% | 798,950 |
| Vanguard Index Funds | 940,813 | Institution | 4.15% | 698,083 |
| Ishares | 723,172 | Institution | 3.19% | 536,594 |
| Delaware Group Equity Funds Iv | 566,666 | Institution | 2.50% | 420,466 |
| T. Rowe Price Small-cap Value Fund, Inc. | 435,070 | Institution | 1.92% | 322,822 |
| Tiaa-cref Funds | 429,563 | Institution | 1.89% | 318,736 |
| Richard A. Paulson | 269,747 | Insider | 1.19% | 200,152 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Mutual Fund Series Trust | 1,125,000 | Institution | 4.96% | 834,750 |
| Vanguard Index Funds | 940,813 | Institution | 4.15% | 698,083 |
| Delaware Group Equity Funds Iv | 566,666 | Institution | 2.50% | 420,466 |
| T. Rowe Price Small-cap Value Fund, Inc. | 435,070 | Institution | 1.92% | 322,822 |
| Tiaa-cref Funds | 429,563 | Institution | 1.89% | 318,736 |
| Fidelity Salem Street Trust | 242,385 | Institution | 1.07% | 179,850 |
| Fidelity Concord Street Trust | 184,450 | Institution | 0.81% | 136,862 |
| Fidelity Commonwealth Trust Ii | 169,383 | Institution | 0.75% | 125,682 |
| Vanguard Scottsdale Funds | 134,149 | Institution | 0.59% | 99,539 |
| Bridgeway Funds, Inc. | 71,873 | Institution | 0.32% | 53,330 |
FAQ
Who Owns Karyopharm Therapeutics (DE:25K0)?
According to the latest TipRanks data, approximately 29.55% of the company's stock is held by institutional investors, 3.63% is held by insiders, and 66.82% is held by public companies and individual investors.
What percentage of Karyopharm Therapeutics (DE:25K0) stock is held by institutional investors?
According to the latest TipRanks data, approximately 29.55% of Karyopharm Therapeutics (DE:25K0) stock is held by institutional investors: 19.83% by mutual funds, 9.56% by ETFs and 0.16% by other institutional investors.
What percentage of Karyopharm Therapeutics (DE:25K0) stock is held by retail investors?
According to the latest TipRanks data, approximately 66.82% of Karyopharm Therapeutics (DE:25K0) stock is held by public companies and individual investors.
Who owns the most shares of Karyopharm Therapeutics (DE:25K0)?
Peter Kolchinsky owns the most shares of Karyopharm Therapeutics (DE:25K0).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
